Article

Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C.C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2024) Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nature Medicine, 30. ISSN 1078-8956

Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C. C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2023) First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: The phase 3 TALAPRO-2 trial. Nature Medicine, 30. pp. 257-264. ISSN 1078-8956